Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Ridaforolimus in Treatment of Sarcoma-SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Ridaforolimus)(8669-011 AM6) (SUCCEED)

This study has been completed.
Ariad Pharmaceuticals
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp. Identifier:
First received: September 28, 2007
Last updated: February 12, 2015
Last verified: February 2015